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ADOPTIVE T CELL THERAPY FOR CANCER (ACT)
In about 20% cases it is not possible to obtain tumor-reactive autologous TILs.
The ability to generate consistently TILs with antitumor activity: it has only been possible to obtain TIL with therapeutic capacity from melanoma samples. Mutation rate higher than in other cancers. Extrapolated to lung cancer associated with smoking?
AARHUS UNIVERSITET Solid tumors present additional challenges to CAR-T cell therapies, given that the tumor environment is strongly immunosuppressive, and the vast majority of known TAAs that could be targeted by CAR-T cells are also expressed at low levels on normal tissues (on-target/off-tumor toxicities)
The T cell-mediated destruction of normal tissue is a major limiting factor in the clinical use of CAR-T cell therapies. One case has been reported in which lowlevel ErbB2 (Her2/neu) expression on lung epithelia may have led to fatal toxicity in a patient infused with CAR-T cells
